Arthus Biosystems

Arthus Biosystems of  Richmond, California, is the first in the world to create a unique series of antibodies against S-adenosylmethionine (SAM, AdeMet, SAMe) and S-adenosylhomocysteine (SAH) that allows immunoassays to be used in the methylation regulation research.

Their research tools also include a better SAM research standard and are  available to scientists and students worldwide to help better understand S-adenosylmethionine (SAM) and S-adenosyl-homocysteine (SAH) and the related processes and behaviors under a variety of research scenarios. Our missions are to promote research that will enhance our knowledge about methylation index,  bridge the gap between what we know about SAM and the potential applications in clinical diagnostic and medication practices to benefit the public. With our high-quality products, personal support, and limitless potential to solve important scientific problems, our biotech company continues to grow and change for the better.



The SAM Molecule 




Methylation Index




SAM Analog and Antibody


 (SAM-e, SAMe, SAM, AdoMet, ademetionine) was discovered in Italy by G. L. Cantoni in 1952. It is made from Adenosine Triphosphate (ATP) and Methionone by Methionine Adenosyltransferase. S-adenosylmethionine is a critical metabolite in most living organisms. 


(SAM) is an important molecule in methionine cycle pathway and one carbon metabolism pathway that are implicated in many metabolic abnomalities found in humans. Methylation index is defined as the ratio of SAM and SAH, which is a better way to evaluate methylation status of humans and other organisms.

One of the important S-adenosylmethionine (SAM) analogs that has been proven to be very useful assisting in SAM related studies is described in detailed in US patent US8344115.